DOW JONES28,992.41-227.57 -0.78%
S&P 5003,337.75-35.48 -1.05%
NASDAQ9,576.59-174.38 -1.79%

UPDATE: Wells Fargo Maintains Overweight On Abbott Laboratories, Raises Target To $103 Notes Co's 'Strong Q4; Robust 2020 Outlook Introduced'; Believes Co. 'delivered three key messages on the Q4 call:'

'(1) ABT remains confident in Libre 2.0/iCGM approval (positive incremental commentary, but no updated timeline provided); (2) ABT expects to sustain its current levels of organic growth; and (3) ABT executing on its

Benzinga · 01/23/2020 16:58

'(1) ABT remains confident in Libre 2.0/iCGM approval (positive incremental commentary, but no updated timeline provided); (2) ABT expects to sustain its current levels of organic growth; and (3) ABT executing on its diverse pipeline and remains selective with regards to M&A'